A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 2, 2004, Pages 380-385

  Chism, Derek B ^a   Hanlon, Alexandra L ^a   Horwitz, Eric M ^a   Feigenberg, Steven J ^a   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Prostate cancer; Radiation therapy; Risk models

Indexed keywords

DECISION MAKING; RADIOTHERAPY; RISK ASSESSMENT; TUMORS;

FREEDOM FROM BIOCHEMICAL FAILURE (FFBF); INTERMEDIATE RISK (IR);

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL MODEL; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RISK ASSESSMENT;

AGED; ANALYSIS OF VARIANCE; HUMANS; MALE; MODELS, STATISTICAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 2442510047     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.059     Document Type: Article

References (22)

1. American Joint Commission on Staging of Cancer. Cancer staging manual. 6th ed:2002;JB Lippincott, Philadelphia
2. Pisansky T.M., Kahn M.I., Bostwick D.G. An enhanced prognostic system for clinically locallized carcinoma of the prostate. Cancer. 79:1997;2154-2161
3. Zagars G.K., Pollack A., von Escenbach A.C. Prognostic factors for clinically localized prostate carcinoma Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 79:1997;1370-1380
4. Hanks G., Hanlon A., Pinover W., et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Physics. 46:2000;823-832
5. Roach M., Lu J., Pilepich M.V., et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 47:2000;609-615
6. Zelefsky M., Fuks Z., Hunt M.A., et al. High dose radiation delivered by intensity modulated confromal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881
7. Benson M.C., Whang I.S., Olsson C.A., et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 147:1992;817-821
8. Zentner P.G., Pao L.K., Benson M.C., et al. Prostate-specific antigen density A new prognostic indicator for prostate cancer. Int J Radiat Oncol Biol Physics. 27:1993;47-58
9. Corn B.W., Hanks G.E., Lee W.R., et al. Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. J Urol. 153:1995;1855-1859
10. D'Amico A.V., Propert K. Prostate cancer volume adds significantly to prostate specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys. 35:1996;273-279
11. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients wtih clinically localized prostate cancer. J Clin Oncology. 18:2000;1164-1172
12. Lyons J., Kupelian P., Mohan D., et al. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology. 55:2000;85-90
13. D'Amico A., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974
14. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881
15. Horwitz E.M., Hanlon A.L., Pinover W.H., et al. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 92:2001;1281-1287
16. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;447-457
18. Cox D.R. Regression models and life tables. J R Stat Soc. 34:1972;187-220
19. D'Amico A., Whittington R., Malkowicz S., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974
20. Zagars G.K., Geara F.B., Pollack A., et al. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Cancer. 73:1994;1904-1912
21. Buyyounouski M.K., Horwitz E.M., Hanlon A.L., et al. Positive prostate biopsy laterality and implications for staging. Urology. 62:2003;298-303
22. Kattan M.W. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients Preoperative application in prostate cancer. Curr Opin Urol. 13:2003;111-116